Key facts
- It has raised $7.5M; the latest was Later Stage VC in Dec 2024.
- Notable investors include Alwin Capital, Heyuan Capital, Ronghe Capital, YMC Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Frasergen
- ·The full record, as it builds
Funding rounds
No funding rounds for Frasergen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Frasergen
Provider of advanced genomic and bioinformatics services intended to support research in human health, agriculture, and environmental sciences. The company offers three-dimensional genome analysis, next-generation and third-generation sequencing, customized bioinformatics software, and database development, enabling scientists, medical researchers, and agricultural institutions to accelerate discovery, improve disease prevention, and enhance biological understanding.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2012
- Employees
- 150
- Website
- frasergen.com/
- Ownership
- Privately Held (backing)
Frasergen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Frasergen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Frasergen in its N-PORT filings yet. We sweep new filings monthly.